Option chain shows key data for Addex Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Addex Therapeutics.

Addex Therapeutics (NASDAQ:ADXN) Stock, Option Chain

Addex Therapeutics

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Apple, Nio, CVS Health, Stellantis, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADXN

ATNI

BIVI

BOOM

ENSC

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

INAB

IRTC

KSCP

MEDP

MKTW

NTBL

SNSE

TCBP

Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

10 Highest-Paying Dividend Stocks In The S&P 500

Earnings

Equities

Eurozone

Commodities

AAMC

AMWD

CSCI

VOXX

S&amp;P 500 Edges Higher; American Woodmark Shares Slide

Energy stocks

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Intraday Update

HAIN

Crude Oil Dips; Addex Therapeutics Shares Spike Higher

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics Ltd

Press Releases

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Addex to Present at the 2025 Swiss Equities Baader Conference

Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025

Addex Reports Full Year 2024 Financial Results and Provides Corporate Update

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Athira Pharma

Aytu BioPharma

Biofrontera

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Durect

Evoke Pharma

Hoth Therapeutics

Impact BioMedical

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Talphera

Traws Pharma

TherapeuticsMD

HC Wainwright & Co.

Comments

Addex Therapeutics

Addex Therapeutics (ADXN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell